Hengrui Pharma
Hengrui Medicine Co., Ltd., commonly known as Hengrui Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 1993, Hengrui has established a strong presence in the global pharmaceutical industry, focusing on innovative drug development, manufacturing, and marketing. The company operates extensively across Asia, Europe, and North America, positioning itself as a key player in oncology, anaesthesia, and imaging agents. Hengrui Pharma is renowned for its commitment to research and development, with a diverse portfolio that includes targeted therapies and biologics. Its unique approach to drug formulation and delivery has garnered recognition, contributing to its market leadership. With numerous accolades and a robust pipeline of products, Hengrui continues to advance healthcare solutions, making significant strides in improving patient outcomes worldwide.
DitchCarbon Score
How does Hengrui Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hengrui Pharma's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hengrui Pharma's reported carbon emissions
In 2023, Hengrui Pharma reported total carbon emissions of approximately 208,280,090 kg CO2e, comprising about 4,898,000 kg CO2e from Scope 1 and about 203,382,080 kg CO2e from Scope 2 emissions. This marks a reduction from 2022, where total emissions were about 203,512,910 kg CO2e, with Scope 1 emissions at approximately 5,993,700 kg CO2e and Scope 2 emissions at about 197,519,220 kg CO2e. In 2021, the company recorded total emissions of about 244,060,250 kg CO2e, with Scope 1 at approximately 8,837,680 kg CO2e and Scope 2 at about 235,222,570 kg CO2e. Hengrui Pharma has set ambitious climate commitments, aiming for carbon neutrality by 2050. The company has established a near-term goal to reduce carbon emissions from both Scope 1 and Scope 2 operations between 2023 and 2025. Additionally, a long-term roadmap was released, committing to peak carbon emissions by 2029. These initiatives reflect Hengrui's dedication to sustainable practices and align with industry standards for climate action. The emissions data and reduction targets are sourced from Jiangsu Hengrui Medicine Co., Ltd., the parent company, and are not cascaded from any other organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 8,837,680 | 0,000,000 | 0,000,000 |
| Scope 2 | 235,222,570 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hengrui Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
